In just 15 years since its formal inception, the Massachusetts General Hospital Cancer Center has evolved into an international leader in cancer research and care

Patients with non-small-cell lung cancer who initially respond to front-line designer therapies but later relapse may soon have another option — a gene-based drug called HKI-272.  At 14 centers worldwide, a phase 2 trial led by DF/HCC has been launched to study the impact of this second-line drug

You might think that Fortune magazine editor Clifton Leaf would be unwelcome in the mainstream cancer community after his highly critical 2004 cover story, "Why We're Losing the War on Cancer (and How to Win It)."

In that article, Leaf, senior editor-at-large and a cancer survivor, argued that cancer research progress is being oversold to the public, and is being slowed by wrong-headed funding policies by the federal government, insufficient focus on important issues like tumor metastasis, and inefficient clinical trial designs

The Dana-Farber/Harvard Cancer Center (DF/HCC) and the University of Massachusetts Boston have received a five-year, $4.3-million grant from the National Institutes of Health (NIH) to develop a strategy to reduce health disparities in Boston neighborhoods and help further diversify the region’s biomedical leadership through new research and training projects

October 3, 2005 - The National Cancer Institute (NCI), part of the National Institutes of Health NIH), announced the implementation of a major component of its $144.3 million five-year initiative for nanotechnology in cancer research

BOSTON –- A newly identified gene expression profile could help predict how patients with advanced ovarian cancer will respond to chemotherapy treatment

February 7, 2005 - Researchers at Children's Hospital Boston and the Dana-Farber Cancer Institute have found an important clue about the origins of the deadly skin cancer melanoma